Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03043053 · ClinicalTrials.gov registry record · Phase 2
The Effects of Oxytocin in Obese Adults
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT03043053: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT03043053 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 61 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03043053, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in obese adults, ages 18-45 years old. Subjects will be randomized to receive of intranasal oxytocin or placebo (3 sprays per nostril, 4 times per day) for 8 weeks. Study visits include screening to determine eligibility, a 2-part baseline visit, and visits every 2 weeks thereafter until week 14, with a safety follow-up visit 6 weeks after the last dose of study drug. Study procedures include behavioral, metabolic, neuroimaging, and endocrine assessments.
Interventions
- DRUG Placebo
- DRUG oxytocin nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2022-07-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03043053
The ClinicalTrials.gov registry entry for NCT03043053 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03043053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03043053 about?
NCT03043053 is a clinical study titled "The Effects of Oxytocin in Obese Adults". This is a randomized, double blind, placebo-controlled study of the effects of intranasal oxytocin in obese adults, ages 18-45 years old. Subjects will be randomized to receive of intranasal oxytocin or placebo (3 sprays per nostril, 4 times per day) for 8 weeks. Study visits include screening to de...
What is the current status of trial NCT03043053?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2017-07-01. Estimated completion is 2022-07-07.
What interventions are being tested in trial NCT03043053?
The interventions under investigation include: Placebo (DRUG), oxytocin nasal spray (DRUG).
Who is sponsoring clinical trial NCT03043053?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.